This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cretton, E M Articles by Sommadossi, J P Search for Related Content PubMed PubMed Citation Articles by Cretton, E M Articles by Sommadossi, J P

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 May; 35(5): 801-807

Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys.

Department of Pharmacology, University of Alabama, Birmingham 35294.

ABSTRACT

The pharmacokinetics and metabolism of 3'-azido-3'-deoxythymidine (AZT) were investigated in rhesus monkeys after subcutaneous administration of 33.3 mg of AZT per kg of body weight alone or in the presence of 100 mg of probenecid per kg. In addition to unchanged drug, two catabolites, 5'-O-glucuronide (GAZT) and 3'-amino-3'-deoxythymidine (AMT), were detected in plasma within 30 min. GAZT exhibited a kinetic profile similar to that of AZT, with an elimination half-life of approximately 1 h, while AMT was more variable, with an apparent half-life of 1.6 +/- 1.5 h. Approximately 90% of the total administered dose was recovered in urine within 24 h as AZT, GAZT, AMT, and the 5'-O-glucuronide of AMT. AZT and AMT demonstrated similar cerebrospinal fluid (CSF) penetration 1 h after AZT treatment, while GAZT poorly crossed the blood-brain barrier. Concomitant administration of probenecid greatly altered the pharmacokinetics of AZT, GAZT, and AMT, resulting in prolongation of their apparent elimination half-lives, increased concentrations in plasma, and marked reduction in renal clearances. In addition, the CSF/plasma concentration ratios for AZT and its catabolites were greatly increased, suggesting that probenecid inhibits efflux of AZT and its catabolites from CSF to plasma. The substantial levels of AMT in plasma suggest that this catabolite affects the pharmacodynamic properties of AZT in relation to its activity against human immunodeficiency virus replication and cytotoxicity to host cells. Enhanced AMT levels in plasma in the presence of probenecid may decrease the therapeutic efficacy of the AZT-probenecid combination.

This article has been cited by other articles:

• Rayner, C. R., Chanu, P., Gieschke, R., Boak, L. M., Jonsson, E. N. (2008). Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid. J Clin Pharmacol 48: 935-947 [Abstract] [Full Text]  
• Pan, G., Giri, N., Elmquist, W. F. (2007). Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine. Drug Metab. Dispos. 35: 1165-1173 [Abstract] [Full Text]  
• Asif, G., Hurwitz, S. J., Obikhod, A., Delinsky, D., Narayanasamy, J., Chu, C. K., McClure, H. M., Schinazi, R. F. (2007). Pharmacokinetics of the Anti-Human Immunodeficiency Virus Agent 1-({beta}-D-Dioxolane)Thymine in Rhesus Monkeys. Antimicrob. Agents Chemother. 51: 2424-2429 [Abstract] [Full Text]  
• Fayz, S., Inaba, T. (1998). Zidovudine Azido-Reductase in Human Liver Microsomes: Activation by Ethacrynic Acid, Dipyridamole, and Indomethacin and Inhibition by Human Immunodeficiency Virus Protease Inhibitors. Antimicrob. Agents Chemother. 42: 1654-1658 [Abstract] [Full Text]  
• Cato, A. III, Qian, J., Hsu, A., Levy, B., Leonard, J., Granneman, R. (1998). Multidose Pharmacokinetics of Ritonavir and Zidovudine in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 42: 1788-1793 [Abstract] [Full Text]